The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

The agency issued its decision on Friday, giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie diet ... FDA's Center for Drug ...

20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ... The agency said that along with the drug, a reduced-calorie diet and increased physical activity should also be ...

It should be used with a reduced-calorie diet and ... the new FDA green light doesn’t expand the number of people who may be eligible for the drug, since the sleep apnea approval is specifically ...

20, the FDA announced that the agency has approved Eli Lilly's Zepbound ... in adults with obesity. The drug is to be paired with a reduced-calorie diet and increased physical activity, the ...

The US Food and Drug Administration has approved a generic once ... type 2 diabetes (T2D), as an adjunct to diet and exercise. The move follows the FDA’s approval last month of a generic version ...

20, 2024 – The FDA has approved remestemcel-L ... the body’s natural anti-inflammatory processes The drug is also the first-ever FDA-approved treatment for children ages 2 months and older ...